| Summary: | Burosumab has a Health Canada indication for the treatment of XLH in adult and pediatric patients one year of age and older. Burosumab is a recombinant human immunoglobulin G subclass 1 monoclonal antibody that binds to the N-terminal domain of FGF23. The Health Canada-recommended starting dose of burosumab in pediatric patients with XLH (one year old to younger than 18 years old) is 0.8 mg/kg of body weight, rounded to the nearest 10 mg, administered by subcutaneous (SC) injection every two weeks. The Health Canada-recommended starting dose of burosumab in adult patients with XLH (18 years of age and older) is 1 mg/kg of body weight, rounded to the nearest 10 mg up to a maximum dose of 90 mg, administered by subcutaneous (SC) injection every four weeks. In both pediatric patients and adults, the dose of burosumab may be adjusted based on serum phosphorus levels, with a maximum dose of 90 mg. Burosumab should be administered by a health professional
|
|---|